The State of the Problem of Achieving Extremely Low LDL Levels

Author(s): Victoria Korneva*, Tatiana Kuznetsova, Ulrich Julius

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 37 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Patients who have achieved very low low-density lipoprotein CH (LDL-C) levels in clinical trials have shown the lowest cardio-vascular risk. The current clinical guidelines set such a concentration for LDL-C as < 1.4 mmol/L. However, the question of minimum permissible target values of the lipids remains unresolved. A number of experimental and clinical studies showed some unfavorable consequences of low LDL-C levels At the same time, the modern arsenal of lipid lowering drugs allows reducing LDL-C levels to extremely low values. This review presents an analysis of literature about the safety of low lipid spectrum parameters.

Keywords: Low-density lipoprotein CH (LDL-C), PCSK9 inhibitors, statins, diabetes mellitus, immune system, malignant neoplasms, brain function.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 37
Year: 2021
Published on: 11 January, 2021
Page: [3841 - 3857]
Pages: 17
DOI: 10.2174/1381612827999210111182030
Price: $65

Article Metrics

PDF: 224